Top Qs
Timeline
Chat
Perspective
DHA-paclitaxel
Investigational drug From Wikipedia, the free encyclopedia
Remove ads
DHA-paclitaxel (or Taxoprexin) is an investigational drug (from Protarga Inc) made by linking paclitaxel to docosahexaenoic acid (DHA), a fatty acid that is easily taken up by tumor cells; the DHA-paclitaxel “appears not to be cytotoxic until the bond with DHA is cleaved within the cell.”[1] The advantage of DHA-paclitaxel over paclitaxel is DHA-paclitaxel's ability to carry much higher concentrations of paclitaxel to the cells, which are maintained for longer periods in the tumor cells, thus increasing their action. With increased activity, DHA-paclitaxel, also known as Taxoprexin, may have a more successful response in cancer patients than Taxol, and it may be able to treat more types of cancer than Taxol has been able to treat.
Remove ads
Clinical trials
In 2007, a phase II clinical trial reported "modest activity in patients with oesophago-gastric cancer".[2]
References
Wikiwand - on
Seamless Wikipedia browsing. On steroids.
Remove ads